VRTX vs INCY — Key Metrics
| Metric | VRTX (VERTEX PHARMACEUTICALS INC) | INCY (INCYTE CORP) |
|---|---|---|
| Price | 536.45 | 117.8 |
| Market Cap | 136.01 Billion | 24.01 Billion |
| P/E (TTM) | 34.23 | 56.36 |
| P/B (Quarterly) | 6.436 | 4.219 |
| P/S (TTM) | 10.5 | 3.99 |
| Net Profit Margin (TTM) | 30.7 | 6.7 |
| Gross Margin (TTM) | 85.5 | 92.7 |
| ROE (TTM) | 20.1 | 7.1 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Greatly Outperform
Recommendation Summary
Stock VRTX is projected to outperform the market, stock INCY is projected to greatly outperform the market. Upfront Recommendation: INCY.
Financial Metrics
| VRTX | Metrics | INCY |
|---|---|---|
| $536.45 | Price | $117.80 |
| — | Market Capitalization | — |
| 34.23 | Price to Earnings Ratio | 56.36 |
| 10.5 | Price to Sales | 3.99 |
| 42.47 | Price to FCF Ratio | 35.06 |
| 12.28 | Price to Gross Profit | 4.31 |
| 32.0 | Price to R&D | 6.99 |
| 11.64 | Price to Current Assets | 4.35 |
VRTX vs INCY at a glance
Vertex Pharmaceuticals INC (VRTX) and Incyte Corp (INCY) are both Biotechnology companies in the Healthcare sector. VRTX is the larger, at $136.0 billion in market value against $24.0 billion for INCY, about 5.7 times the size.
On trailing-twelve-month figures, VRTX trades at 34.2 times trailing earnings and INCY at 56.4; net profit margins are 30.7% and 6.7%.
The Upfront Investment model currently rates VRTX Outperform and INCY Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.